Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer

Duell, Thomas; Kappler, S.; Knöferl, B.; Schuster, Tibor; Hochhaus, Jason; Morresi‐Hauf, Alicia; Huber, RM; Tufman, Amanda; Zietemann, Vera

doi:10.1016/j.ctrc.2015.08.004

Cited by 9 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study shows that younger patients developed more brain metastases in the course of their disease, also described in previous reports. 24-26 Duell et al 25 recently reported that brain metastases are frequent among younger patients (age < 65 years), females, never smokers, and patients with early-disease stage. Our study did not demonstrate any gender predominance in patients who developed brain metastases, but in both age groups they were significantly more likely to harbor EGFR mutations.…”

Section: Discussionmentioning

confidence: 99%

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

Suidan

Roisman

Rozenblum

et al. 2019

JGO

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

Suidan

Roisman

Rozenblum

et al. 2019

JGO

View full text Add to dashboard Cite

“…Unfortunately, most lung cancers present at a clinically advanced stage [2,3]. PET/CT is now an important cancer imaging tool, both for diagnosis and staging, as well as offering prognostic information based on response.…”

Section: Discussionmentioning

confidence: 99%

“…18F-FDG uptake deficiency from Non small-cell lung cancer has not well addressed. 3. A case of cerebral metastasis with 18F-FDG uptake deficiency was presented.…”

Section: Introductionmentioning

confidence: 99%

Cerebral metastasis with 18F-FDG uptake deficiency from non small-cell lung cancer

Wang¹,

Huang²,

Wang³

et al. 2017

Glob Drugs Therap

View full text Add to dashboard Cite

A 60-year-old Chinese man was admitted to Hospital with the history of intermittent convulsion of left upper limb with numbness of left lower limb for more than half a month, without headache, dizziness, nausea, vomiting and other symptoms. Brain magnetic resonance imaging (MRI) revealed an occupying lesion in right frontal lobe (Figure 1 A-C), then brain metastasis and gliomas were considered. A chest X-ray was taken, and no abnormality was detected. Tumor markers were slightly higher and results were summarized. Subsequently, he was referred for an FDG PET/CT imaging to evaluate the whole-body, the images revealed a low-density lesion in right frontal lobe with distinct borderline, and FDG uptake was deficient completely, less than that of white matter ( Figure 2). Meanwhile, a solitary pulmonary nodule was detected in upper lobe of the right lung with higher FDG uptake (standardized uptake values (SUVmax: 2.1) (Figure 3), without any other abnormality in other organs. DiscussionLung cancers form a leading cause of death worldwide, of which more than 80% show non-small cell histology [1]. Unfortunately, most lung cancers present at a clinically advanced stage [2,3]. PET/CT is now an important cancer imaging tool, both for diagnosis and staging, as well as offering prognostic information based on response.Because of the high FDG uptake in gray matter, the contrast of the uptake from the tumor versus normal brain tissue decreases, leading to low sensitivity. It is accepted that the correlation of grades with 18 F-FDG showed high-grade brain tumor demonstrated hypermetabolism with high FDG uptake, while low-grade brain tumors revealed low levels of glucose metabolism with less than, equal to, or slightly higher than that of white matter. Cerebral metastases mainly occur in the supratentorial AbstractLung cancers form a leading cause of death worldwide. The prognosis in lung cancer is greatly worsened by the presence of metastases, the brain is an extremely common metastatic site. Non small-cell lung cancer (NSCLC) was more frequently associated with hypermetabolic metastatic brain lesions than small-cell lung cancer (SCLC).18 F-FDG PET/CT is increasingly used in detecting and staging of lung cancer as single "one stop shop" method. However FDG uptake deficiency from NSCLC has not well addressed. Here we presented a particular case of 18 F-FDG PET/CT for cerebral metastasis with 18 F-FDG uptake deficiency from NSCLC.

show abstract

“…Among patients with NSCLC, up to 22% will have CNS metastases at initial presentation , and up to 40% will develop CNS metastases during the course of disease . Gain‐of‐function mutations in the EGFR gene are found in about 10%–20% of NSCLC cases .…”

Section: Cns Metastasesmentioning

confidence: 99%

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies

et al. 2018

View full text Add to dashboard Cite

Driver gene fusions involving receptor tyrosine kinases have been identified across a wide range of tumor types, including primary central nervous system (CNS) tumors and extracranial solid tumors that are associated with high rates of metastasis to the CNS (e.g., lung, breast, melanoma). This review discusses the systemic therapies that target emerging gene fusions, with a focus on brain-penetrant agents that will target the intracranial disease and, where present, also extracranial disease.

show abstract

Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer

Cited by 9 publications

References 28 publications

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

Cerebral metastasis with 18F-FDG uptake deficiency from non small-cell lung cancer

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies

Contact Info

Product

Resources

About